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Abstract: Background 
Bacille Calmette-Guérin (BCG) is routinely given at birth in 
tuberculosis-endemic settings due to its protective effect against 
disseminated tuberculosis in infants. BCG is however contraindicated in 
HIV-infected infants. We investigated whether delaying BCG vaccination to 
14 weeks of age affected vaccine-induced antibody responses to 
Haemophilus influenza type b (Hib)-conjugate, pertussis, tetanus and 
Hepatitis B (HBV) vaccines, in HIV-exposed uninfected (HEU) and -
unexposed uninfected (HUU) infants.  
Methods 
Infants were randomized to receive BCG at birth or at 14 weeks of age. 
Blood was taken at 14, 24, and 52 weeks of age and analyzed for Hib, 
pertussis, tetanus and HBV specific antibodies. 
Results 
BCG was given either at birth (106 infants, 51 HEU) or at 14 weeks of age 
(74 infants, 50 HEU). The timing of BCG vaccination did not influence the 
antibody response to any antigen studied. However, in a non-randomised 
comparison, HEU infants had higher Hib antibody concentrations at weeks 
14 and 24 (p=0.001 and <0.001 respectively) and pertussis at week 24 
(p=0.003). Conversely, HEU infants had lower antibody concentrations to 
HBV at 14 and 52 weeks (p=0.032 and p=0.031) with no differences in 
tetanus titres.   
Conclusions 
HIV exposure, but not the timing of BCG vaccination, was associated with 
antibody concentrations to Hib, pertussis, HBV and tetanus primary 
immunization.  
Clinical Trial Registration: DOH-27-1106-1520 
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Highlights:  
 Timing of BCG vaccination did not influence antibody levels to Hib, 
pertussis, tetanus or HBV 
 Effects of early versus late BCG vaccination did not differ between HIV-
exposed and –unexposed groups 
 HIV-exposure without infection was associated with increased Hib and 
pertussis antibody concentrations 
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ABSTRACT  42 
Abstract word count: 208 43 
Background 44 
Bacille Calmette-Guérin (BCG) is routinely given at birth in tuberculosis-endemic settings 45 
due to its protective effect against disseminated tuberculosis in infants. BCG is however 46 
contraindicated in HIV-infected infants. We investigated whether delaying BCG vaccination 47 
to 14 weeks of age affected vaccine-induced antibody responses to Haemophilus influenza 48 
type b (Hib)-conjugate, pertussis, tetanus and Hepatitis B (HBV) vaccines, in HIV-exposed 49 
uninfected (HEU) and -unexposed uninfected (HUU) infants.  50 
Methods 51 
Infants were randomized to receive BCG at birth or at 14 weeks of age. Blood was taken at 52 
14, 24, and 52 weeks of age and analyzed for Hib, pertussis, tetanus and HBV specific 53 
antibodies. 54 
Results 55 
BCG was given either at birth (106 infants, 51 HEU) or at 14 weeks of age (74 infants, 50 56 
HEU). The timing of BCG vaccination did not influence the antibody response to any antigen 57 
studied. However, in a non-randomised comparison, HEU infants had higher Hib antibody 58 
concentrations at weeks 14 and 24 (p=0.001 and <0.001 respectively) and pertussis at 59 
week 24 (p=0.003). Conversely, HEU infants had lower antibody concentrations to HBV at 60 
14 and 52 weeks (p=0.032 and p=0.031) with no differences in tetanus titres.   61 
Conclusions 62 
 4 
HIV exposure, but not the timing of BCG vaccination, was associated with antibody 63 
concentrations to Hib, pertussis, HBV and tetanus primary immunization.  64 
Clinical Trial Registration: DOH-27-1106-1520 65 
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BACKGROUND 81 
Approximately 1.4 million children under five years of age die annually of vaccine 82 
preventable infectious diseases.[1] Maternal and paediatric HIV infections contribute 83 
considerably to the burden of infectious disease in developing countries, and HIV-exposed 84 
infants constitute up to 30% of infants born in the public health sector in settings with high 85 
burden of HIV such as South Africa.[2] Studies of vaccine responsiveness amongst this 86 
subpopulation are limited but are important considering their high morbidity and mortality, 87 
even in the absence of infant HIV infection. [3-7]  88 
Many vaccines rely on inducing antibodies to pathogens or their toxins. Although maternal 89 
IgG crosses the placenta in utero providing some protection against vaccine preventable 90 
infections, infant IgG and IgA responses to pathogens remain relatively weak in the first 12 91 
months of life. [8, 9] Despite B-cell priming in neonates generating memory B cells, 92 
maternal antibody can inhibit primary humoral responses [6]. Antenatal HIV exposure has 93 
been associated with lower specific antibody levels in HIV-exposed uninfected (HEU) 94 
infants than HIV-unexposed uninfected infants (HUU) at birth, although subsequent 95 
responses in HEU infants to certain vaccines may be better than HUU infants, perhaps due 96 
to less inhibition.[7] The development of vaccines or vaccination strategies to induce early 97 
protective immune responses in infants is a major challenge in vaccinology.  98 
BCG induces robust Th-1 type cellular immune responses, even at birth.[10-12] Apart from 99 
its protective effect against disseminated tuberculosis (TB) in young children, [13] BCG is 100 
associated with other “non-specific” protective effects and decreases non-TB-related child 101 
morbidity and mortality in settings with high background rates of infectious morbidity.[14, 102 
15] For example, trials from West Africa showed that BCG reduces neonatal mortality by 103 
more than 40%, mainly by preventing neonatal sepsis and respiratory infections.[16, 17] In 104 
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addition, Ota et al found that BCG enhanced humoral immunity to oral polio and hepatitis B 105 
vaccinations but not to tetanus and diphtheria toxoids, while de Castro et al found that BCG 106 
vaccination at birth may decrease hospitalization due to respiratory infection and sepsis, 107 
due to heterologous protection. [12, 18]  108 
In addition to adding new vaccines to the Expanded Programme on Immunization (EPI) 109 
schedule, it is necessary to assess potential vaccine interactions as well as specific and non-110 
specific vaccine effects of existing vaccines, with consideration of maternal HIV status. [19] 111 
BCG-related effects on unrelated vaccine-induced antibody responses could be important in 112 
settings with high HIV prevalence, where BCG is still routinely given at birth.  Based on 113 
concerns of BCG vaccine safety in HIV-infected infants, delaying BCG vaccination in HIV-114 
exposed infants until HIV has been excluded, is a relevant strategy, but its timing could 115 
influence vaccine responsiveness. [20] 116 
We investigated the effect of delayed BCG vaccination on antibody responses to Hib-117 
conjugate, whole cell Bordetella pertussis (wP), tetanus toxoid (TT) and hepatitis B (HBV) 118 
vaccines, in HEU and HUU infants.  We hypothesized that BCG vaccination at birth would 119 
increase antibody responses to other vaccines through induction of non-specific 120 
immunological effects, and that these responses would be more pronounced in HIV-exposed 121 
infants. 122 
METHODS 123 
Study setting 124 
This study was conducted from 1 April 2006 to 31 March 2008 at the community-based Site 125 
B Midwife Obstetric Unit and well baby clinic in Khayelitsha, Cape Town, Western Cape 126 
Province, South Africa, where the maternal HIV prevalence was 32.7 % (95% CI: 29.5-127 
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35.9%) in 2008 [21]  with a well-established prevention of mother to child HIV 128 
transmission (PMTCT) program.  129 
During the study, the South African EPI recommended intradermal BCG vaccination (0.05 130 
ml reconstituted vaccine, Danish strain BCG, Statens Serum Institute, 1331) and oral live 131 
polio (OPV, Sabin, Sanofi Pasteur, France, 2 drops orally) at birth. Diphtheria and TT 132 
vaccines, wP and Hib conjugate vaccines (PRP-T) administered as DTP-Hib (TETRActHib, 133 
Sanofi Pasteur, France, 0.5ml intramuscular) were recommended at 6, 10 and 14 weeks of 134 
age, and were co-administered with Hepatitis B (HBV; Heberbiotec, Cuba, 0.5ml; 135 
intramuscular) and OPV. Live measles vaccine (Sanofi Pasteur, France, 0.5ml intramuscular) 136 
was recommended at 9 months. As per South African guidelines, pregnant women did not 137 
receive anti-tetanus vaccination. BCG coverage was estimated at 99% during 2005.[22] 138 
Eligibility and randomization 139 
Recruitment, enrolment, BCG vaccination and surveillance were carried out as previously 140 
described[23]. Briefly, this was an individual, single-blinded, exploratory randomized Phase 141 
2 clinical trial investigating immunological effects of early versus delayed BCG vaccination 142 
in HIV-exposed and –unexposed infants (DOH-27-1106-1520). Pregnant HIV-positive and –143 
negative women were recruited at the midwife obstetric unit.. Enrolment was stratified by 144 
maternal HIV status to ensure that two-thirds of infants (n=120) were HIV-exposed and 145 
one-third (n=60) HIV-unexposed (control group), using 2 separate randomization lists. 146 
Infants were randomized to BCG, given intradermally in the right deltoid area, at birth 147 
(routine BCG), versus at 14 weeks of age (delayed BCG). The concealed envelope method 148 
was used by the study nurse, who enrolled participants antenatally, and was blinded to 149 
study allocation. Stratified randomization (2 separate lists for HIV-infected and uninfected 150 
women) was completed by an independent statistician, using randomization with blocks 151 
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varying in size from 2 to 6 with random ordering. Study nurses who assessed and followed 152 
infants were not blinded to treatment allocation.   153 
Women with pregnancies of estimated 32 or more weeks gestation were screened for 154 
eligibility after routine testing for HIV and written informed consent was obtained. The 155 
following were postnatal infant exclusion criteria: stillbirth, birth weight <1.6 kg, severe 156 
congenital malformation, asphyxia or other severe illness at birth since under these 157 
circumstances, BCG is not routinely given in South Africa.  Protocol violators were defined 158 
as infants randomized to receive delayed BCG vaccination at 14 weeks, but who were 159 
inadvertently given BCG at birth by routine personnel.  160 
Study measures and follow-up 161 
Infant HIV testing and clinical follow-up were performed as previously described.[23] 162 
Briefly, a single infant HIV DNA polymerase chain reaction test (Amplicor, Roche Molecular 163 
Diagnostics, Pleasanton , CA) was routinely offered at 6 and at 14 weeks of age. The routine 164 
testing algorithm at the time recommended testing at 14 weeks of age only.  Follow-up was 165 
carried out on the same premises, at the  Site B well baby clinic, where infants would have 166 
attended routine clinical care.   Antibody levels were classified using the following accepted 167 
measures. Anti-Hib capsular polysaccharide (PRP-T) IgG antibodies were measured using 168 
the VaccZymeTM Human Anti Hib Enzyme Immunoassay kit (MK016, The Binding Site Ltd, 169 
Birmingham, England). Measurement of specific IgG antibodies to Bordetella pertussis was 170 
completed using pertussis toxin (PT) and filamentous hemagglutinin (FHA) as antigen 171 
preparation using the SERION ELISA classic kit (Serion Immundiagnostica GmbH, 172 
Würzburg, Germany). Anti-tetanus IgG was measured with the SERION ELISA classic kit 173 
(Serion Immundiagnostica GmbH, Würzburg, Germany). Specific IgG against Hepatitis B 174 
surface antigen (HBsAg) were quantified using a semi-automated ELISA method (AxSym 175 
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HBsAb, Abbott Diagnostics, measuring range: 2-1000 mIU/ml). Hib antibody level was 176 
classified as protective if >1 mg/ml and non-protective level if ≤1 mg/ml.[24] Since there is 177 
no correlate of protection against pertussis, anti-pertussis antibody was classified positive if 178 
>30 FDA-U/ml, indeterminate if 20-30F FDA-U/ml and negative if <20 FDA-U/ml, as 179 
defined by the manufacturer.[25] Tetanus antibodies were classified as having no immunity 180 
if <0.01 IU/ml; no safe immunity if 0.01-0.1 IU/ml; sufficient immunity if 0.11-5.0 IU/ml and 181 
long-term immunity: >5.0 IU/ml, and sufficient or long-term immunity were considered 182 
protection for the purposes of analysis.[26] HBsAb concentrations <10 mIU/ml were 183 
classified as negative and when ≥ 10 mIU/ml as positive, based on standard international 184 
criteria. [27] 185 
 186 
In a subset of participants (n=38, with 17 HEU and 21 HUU infants) with sufficient 187 
additional stored sera, the relative avidity of IgG against Hib capsular polysaccharide was 188 
measured to assess qualitative response (VaccZyme Hib ELISA accessory pack, The Binding 189 
Site Ltd, Birmingham, U.K.). Typical reported values range from 26.4- 68.3 mg/ml.  190 
Statistical analysis 191 
The primary end point was the difference in the magnitude of antibody responses to Hib, 192 
pertussis, HBV and TT between infants in the early and the delayed BCG groups at 14 weeks 193 
of age. Secondly, the effect of HIV exposure on vaccine antibody titres was investigated at 194 
week 14, 24 and 52. Sample size estimates for this exploratory study were calculated 195 
assuming a 30% difference in vaccine antibody responses between BCG vaccinated and 196 
unvaccinated infants, and a 30% difference between HIV-exposed and unexposed infants, at 197 
week 14. HIV-infected infants (n=2) were excluded from analysis.  198 
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The effect of timing of BCG vaccination and HIV exposure on the proportion of responders 199 
was compared using the Chi-squared test or Fisher’s exact where appropriate; effect 200 
estimates (OR; 95% CI) were calculated. Log-transformed data were used to compare mean 201 
antibody titres. Antibody concentrations of zero or below the assay cutoff were given an 202 
arbitrary value of half the cutoff for geometric mean concentration (GMC) calculation. The 203 
2-sided t test was used for comparison of GMC antibody values.  204 
A base-10 linear regression model with log-transformed values was used to compare the 205 
proportion of “protective” responses to Hib, pertussis, HBV and TT vaccines at week 14 206 
using BCG vaccination as primary exposure variable. Other variables included were either 207 
specified in the study hypothesis and included HIV exposure, or were known to influence 208 
vaccine antibody responses such as sex and birth weight [28-30]. Statistical significance 209 
was inferred at the 2-sided 0.05 level.  SPSS software (version 16.0, Chicago, Ill) was used 210 
for analyses. Missing values were excluded from analysis. The CONSORT guidelines were 211 
used for reporting. [31] The Stellenbosch University Human Research Ethics Committee 212 
approved the study (trial number DOH-27-1106-1520). 213 
RESULTS 214 
120 HIV-infected and 60 HIV-uninfected women were enrolled during pregnancy. Following 215 
randomization, 5 infants (2.8%) were excluded; 1 mother withdrew from the study due to 216 
geographic relocation and 4 HIV-exposed infants were stillborn. These infants were 217 
replaced with additional randomized participants.. 218 
Figure 1 provides an overview of the study cohort, per protocol. Randomization of infants 219 
resulted in balance for maternal HIV status, infant sex, mean birth weight, maternal CD4+ T 220 
cell count and maternal HAART (Table 1).  The mean birth weight overall was 3206 grams 221 
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(standard deviation; SD: 44). Only 6 infants (3.33%) had birth weight <2500 grams. The 222 
mean maternal CD4+ T lymphocyte amongst HIV-infected women was 363 cells/mm3 (SD 223 
23.7). Of HIV-infected women, 27 (15%) had a CD4+ T lymphocyte count ≤200 cells/mm3; 224 
these women were all on highly active antiretroviral therapy (HAART; Zidovudine, 225 
Lamivudine and Nevirapine).  226 
Of the 90 infants randomized to delayed BCG, 16 were inadvertently given immediate BCG 227 
by routine labour ward personnel, resulting in 106 infants in the birth (67, 63.2% HIV-228 
exposed) and 74 infants (46, 62.2% HIV-exposed) in the delayed BCG groups, respectively. 229 
Analysis was therefore based on actual vaccination (per protocol) status. 230 
Proportion of infants with positive/protective antibody concentrations  231 
Proportions of infants with “protective” antibody concentrations to Hib, pertussis, TT and 232 
HBV are reflected in Supplementary Table 2. In general, the proportion of infants with 233 
“protective” Hib and pertussis titres was low at all timepoints. Only 62% of infants had 234 
antibody concentrations to Hib correlating with protective immunity at week 24, following 235 
verified completion of weeks 6, 10 and 14 vaccinations; the level declined to 35% at week 236 
52. At week 24, 48% of infants had positive  pertussis titres; 45% of infants maintained 237 
positive titres at week 52. In contrast, the proportion of infants with positive/protective 238 
titres to TT and HBV vaccines was high with all infants having antibody concentrations 239 
correlating with sufficient or long-term protective immunity to tetanus vaccine at week 24; 240 
positive responses to HBV were detected in all infants. Only 1.2% of infants lacked 241 
protective response to TT at week 52.  242 
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Effect of BCG vaccination timing on antibody concentrations  243 
Overall, there was no detectable effect of BCG vaccination timing on the GMC antibody titres 244 
to Hib, pertussis, or TT at weeks 14, 24 or 52 (Figure 2). There was a trend for higher 245 
antibody responses to HBV in the birth BCG group at week 14 (GMC in birth group: 30.5 vs. 246 
10.1in the delayed group; p=0.090). Similarly, there was no observed effect of BCG on the 247 
proportion of infants with “protective” antibody concentrations (Supplementary Table 1).  248 
Results were similar comparing the proportion of infants with “protective” responses in the 249 
birth and delayed BCG groups at 14 weeks when infants in the protocol violator group were 250 
excluded (data not shown). 251 
Effect of in utero HIV exposure on antibody concentrations  252 
Stratified analysis of antibody titres between HIV-exposed and unexposed infants produced 253 
similar results in both the birth and delayed BCG groups (data not shown); the birth and 254 
delayed groups were therefore combined for further analysis. In the combined analysis, 255 
HIV-exposed infants consistently demonstrated higher GMC antibody titres to Hib at weeks 256 
14 and 24, and also to pertussis at week 24 (Figure 3a-b).  These higher concentrations 257 
corresponded to a higher proportion of HIV-exposed infants with positive/protective 258 
antibody concentrations to Hib at week 14 (OR: 1.75; 95% CI: 1.17-2.63, p=0.007) and week 259 
24 (OR: 2.09; 95% CI: 1.37-3.17, p=0.001) and to pertussis at week 24 (OR: 1.80; 95% CI: 260 
1.19-2.72, p=0.007) (Table 2). Conversely, HIV-exposed infants had significantly lower GMC 261 
of HBV antibody at week 14 and week 52, although all were above positive/protective 262 
concentrations (Figure 3d). Antibody concentrations to tetanus vaccine were similar 263 
between HIV-exposed and unexposed infants (Figure 3c). 264 
Effect of BCG vaccination timing on antibody concentrations in HIV-exposed infants 265 
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Because delaying BCG vaccination until 14 weeks of age would be most relevant for infants 266 
born to HIV-positive mothers, we compared the effects of BCG vaccination at birth versus 267 
14 weeks of age in HIV-exposed infants. There was no detectable effect of BCG vaccination 268 
on the GMC of antibody to Hib, pertussis, tetanus of HBV at weeks 14, 24, or 52 269 
(Supplementary Figure 1).  270 
Predictors of antibody titres against against Hib and pertussis 271 
In a multivariable base-10 linear regression model with log10-transformed values for 272 
factors (including BCG vaccination as primary predictor and HIV exposure status, birth 273 
weight and sex as covariates) associated with “protective” anti-Hib concentration at 14 274 
weeks of age (including BCG vaccination as primary predictor and HIV exposure status, 275 
birth weight and sex as covariates), only HIV exposure remained associated with higher 276 
concentrations (coefficient 0.47; 95% CI: 0.21-0.72; p<0.001; adjusted R2=0.101) (Table 3); 277 
the timing of BCG vaccination was not a predictor. In a similar model for pertussis, none of 278 
the predictors were associated with “protection” against pertussis at week 14 (adjusted 279 
R2=0.020; Table 3). For boththe Hib linear regression models, a plot of the residuals versus 280 
the antibody titres for Hib and pertussis were randomly distributed, indicating that a linear 281 
regression model was appropriate for analysis. For pertussis, a plot of the residuals versus 282 
the antibody titres revealed a single outlier; removal of this single outlier did not alter the 283 
model. Linear regression analyses of predictors for positive responses to TT or HBV were 284 
not completed since all infants had sufficient or long-term immunity to TT, and 99.2% 285 
immunity HBV at week 14, respectively. 286 
Formatted: Superscript
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Qualitative Hib antibody  287 
Qualitative analyses for Hib were completed in 38 infants with available serum samples, in 288 
17 HEU and in 21 HUU infants. The mean binding index was 72.06 (SD 45.67) classified as 289 
“high or adequate”. There was no difference between the mean index in HEU and HUU 290 
infants (mean: 66.01; SD: 18.41 in HEU vs. 76.95; SD: 59.42 in HUU infants; p=0.470). 291 
DISCUSSION 292 
In this exploratory randomized controlled trial, the timing of BCG vaccination did not alter 293 
antibody responses to Hib, pertussis, HBV and TT vaccines in HEU or HUU infants. Despite a 294 
trend for increased antibody responses to HBV, there was no evidence for BCG-induced 295 
increased HBV antibody concentrations, both when responses were measured at 14 weeks 296 
(comparing the effect of BCG given at birth to infants who had not yet received BCG), and at 297 
24 and 52 weeks (comparing the effect of BCG given at birth to BCG given at 14 weeks). In a 298 
non-randomised comparison, we found that HIV-exposed infants had significantly higher 299 
antibody concentrations to pertussis and Hib than HIV-unexposed infants, following 300 
vaccination.  This study is limited by the lack of data on maternal and baseline (birth) infant 301 
antibody responses, and a lack of correlation with clinical endpoints. The protocol 302 
violations  (vaccination with BCG when subjects were randomized to the delayed BCG 303 
group) and high loss to follow-up may also have introduced bias. We did not find any 304 
differences at birth in sex, birth weight, or maternal HIV status between infants in the 305 
protocol deviation group, and infants who were vaccinated as per randomisation schedule, 306 
but this does not exclude bias (for example, if loss to follow-up was associated with 307 
differences in response to immunization).  308 
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We found that the proportion of children with Hib antibody >1 mg/ml were consistently of 309 
greater magnitude amongst HEU compared to HUU infants in both the early and delayed 310 
vaccination groups and remained significant after controlling for the timing of BCG 311 
vaccination, birth weight and sex, at week 14.   The proportion of children with anti-312 
pertussis antibody >30 FDA-U/ml at 24 weeks of age was also higher amongst HIV-exposed 313 
infants. These data are consistent with our own and other published data.[5, 23] The higher 314 
observed antibody responses to Hib and pertussis amongst HEU infants may be due to 315 
reduced maternal-infant placental antibody transfer in the presence of maternal HIV 316 
infection. Jones et al showed that HEU infants had lower concentrations of specific 317 
antibodies at birth than HUU infants to Hib, wP, pneumococcus and tetanus vaccines, in the 318 
identical study setting.[7] Maternal antibodies can inhibit infant responses to measles, 319 
tetanus, wP, and Hib vaccines, although this effect varies considerably between different 320 
vaccines and studies.[32-34] Another explanation for this may be non-specific T cell 321 
activation as a result of in utero, peripartum or postpartum HIV exposure and increased 322 
immune maturity.[35]  323 
Maternal infections, including HIV, can negatively impact placental integrity and maternal-324 
foetal antibody transfer. A study amongst Kenyan HIV-infected women and their infants 325 
showed that high maternal viral load was associated with reduced transplacental transfer of 326 
measles antibodies.[36] Although vaccination of women during pregnancy leads to 327 
transplacental transfer of antibodies, high total maternal IgG concentrations may lead to 328 
decreased antibody concentrations in infants; this effect can last until up to 12 months of 329 
age.[37] In this study, we have no data on prevaccination antibody levels, and therefore 330 
cannot distinguish whether HEU infants had poor antibody responses due to inherent 331 
deficiencies in immunity, or due to differences in passive maternal antibody levels. 332 
Although persistence of maternal antibodies may limit infant antibody responses, priming 333 
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of infant T-cell responses are unaffected by these passively transferred antibodies, which 334 
may explain why humoral responses are altered, but not cellular responses [37, 38]. In this 335 
study, we did not measure T cell responses to vaccines, but we found compromised IFN- 336 
ELISPOT responses in HEU.[23] Antibodies alone are a convenient yet imperfect measure of 337 
vaccine-induced effects, as cell-mediated immunity is likely also an important component of 338 
protection against vaccine-preventable disease.  339 
Our finding that BCG timing had no effect on antibody responses to unrelated vaccines is 340 
inconsistent with data from a single study from Ota et al from the Gambia, a setting with 341 
high infant mortality but low HIV prevalence. Here, giving BCG at birth markedly increased 342 
the cellular and antibody responses to HBV in low birth weight infants at 18 weeks. [12] 343 
BCG enhanced antibody responses to OPV, but only when given at the time of boosting. BCG 344 
had no detectable effect on antibody responses to TT (consistent with our findings) and 345 
diphtheria toxoid vaccines at 18 weeks. A proposed mechanism for these BCG effects on 346 
HBV and OPV responses is the enhanced activation of T lymphocytes by dendritic cells and 347 
BCG- enhanced induction of memory B cells. Unlike in the Gambia, infants in South Africa 348 
receive OPV but not HBV at birth. This may partly explain the lack of effect of BCG on 349 
response to HBV in our study. However, given the almost universally protective immunity 350 
elicited by HBV vaccine in infants, the clinical relevance of changes in responsiveness due to 351 
concomitant BCG vaccination is unknown.  352 
The low proportion of infants in our study with “protective” antibody to Hib and pertussis 353 
at 24 weeks, 10 weeks after vaccination at week 14, is concerning. Low responses confirm 354 
that boosting is essential, as already practiced in the EPI. However, the coverage of DTP-Hib 355 
4 boosting at 18 months was low (<60%) ii routine care at the time of the study, which 356 
leaves a large gap in “protective” immunity. Hussey et al reported similar low levels of 357 
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protective antibody responses (69.1%) following vaccination with the same Hib vaccine 358 
amongst South African infants at 18 weeks of age in an adjacent community.[38] A recent 359 
outbreak of pertussis in Bloemfontein, South Africa, confirms the need for better 360 
immunization practices and suggests that young children are vulnerable and can contribute 361 
to its spread [39]. 362 
Our findings suggest that the timing of BCG vaccination does not have a major effect on the 363 
antibody responses to Hib, pertussis, tetanus and hepatitis B vaccines amongst South 364 
African infants; however, delaying BCG vaccination to 14 weeks of age may deny children 365 
the possible beneficial non-specific reductions in pneumonia and sepsis after BCG at birth, 366 
[16, 17] and it may affect cell-mediated responses to other vaccines and alter the clinical 367 
effects (neither of which were assessed in this study). Although antibody responses to Hib 368 
and pertussis were higher amongst HIV-exposed than HIV-unexposed infants, they were not 369 
“protective” in a third of infants by 52 weeks of age. These findings support further 370 
investigation into optimizing infant vaccination strategies in settings with high HIV 371 
prevalence.  372 
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Figure and Table Captions: 505 
 506 
Figure 1: Flowchart of BCG-vaccinated infants investigated for serum antibody levels 507 
following a per protocol analysis. 508 
Table 1. Characteristics of 180 infants randomized to BCG at birth or delayed BCG 509 
vaccination at 14 weeks of age, by randomization arm. 510 
Figure 2. Concentration of antibody titres to a) Hib, b) pertussis, c) tetanus and d) HBV 511 
measured at 14, 24, and 52 weeks of age in infants who received BCG at birth (dark grey 512 
dots) vs. infants who received delayed BCG at 14 weeks of age (light grey dots), regardless 513 
of HIV-exposure status. Shaded area indicates “protective” antibody concentrations. Bar and 514 
error bars represent geometric mean concentration (GMC) with 95% confidence interval. 515 
Figure 3.  Concentration of antibody titres to a) Hib, b) pertussis, c) tetanus and d) HBV 516 
measured at 14, 24, and 52 weeks of age in HIV-exposed infants (dark grey dots) vs. HIV-517 
unexposed infant (light grey dots), regardless of timing of BCG vaccination. Shaded area 518 
indicates “protective” antibody concentrations. Bar and error bars represent geometric 519 
mean concentration with 95% confidence interval. 520 
 24 
Table 2.  Proportions of infants with “protective” antibody levels to Haemophilus influenza 521 
b, whole cell pertussis, tetanus toxoid and hepatitis B vaccines comparing HIV-exposed and 522 
–unexposed infants, regardless of timing of BCG vaccination (summary data). 523 
Table 3.  Multiple linear regression for predictors of “protective” antibody titres to 524 
Haemophilus influenzae b conjugate vaccine and whole cell B. pertussis at 14 weeks of age 525 
(N=165). 526 
Supplementary Table 1.  Proportion of infants with “protective” antibody levels to 527 
Haemophilus influenza b, whole cell pertussis, tetanus toxoid and hepatitis B vaccines at 14, 528 
24 and 52 weeks of age in infants receiving BCG at birth vs. infants receiving delayed BCG 529 
vaccination at 14 weeks of age.  530 
Supplementary Table 2. Antibody concentrations Haemophilus influenza b (HIB), whole cell 531 
pertussis, tetanus toxoid (TT), and hepatitis B vaccines (HBV) at 14, 24 and 52 weeks 532 
(N=165) regardless of HIV exposure or timing of BCG vaccination (summary analysis).  533 
Supplementary Figure 1. Antibody titres in HIV-exposed infants to a) Hib, b) pertussis, c) 534 
tetanus and d) HBV measured at 14, 24, and 52 weeks of age in infants who received BCG 535 
vaccination at birth (black dots) vs. infants who received delayed BCG vaccination at 14 536 
weeks of age (white circles). Shaded area indicates “protective” antibody concentrations. 537 
Bar and error bars represent geometric mean concentration (GMC) with 95% confidence 538 
interval. 539 
 540 
  BCG at birth 
(N=106) 
Delayed BCG at 14 weeks 
(N=74) 
Comparison 
of birth vs. 
delayed 
arms 
 HIV-exposed 
(N=67, 63.2%)) 
HIV-
unexposed 
(N=39, 36.8%) 
 
p value HIV-exposed 
(N=46, 62.2%) 
HIV-
unexposed 
(N=28, 37.8%) 
 
p value p value 
Female sex (%) 31 (46.2%) 18 (46.2%) 0.99 21 (45.6%) 13 (46.4%) 0.95 0.97 
Mean birth weight, grams  
(standard error) 
3250 (60) 3240 (120) 0.95 3170 (60) 3200 (80) 0.73 0.42 
Mean maternal CD4+ T cell count 
 (standard error) 
355 (28) N/A 386 (28) N/A 0.47 
Maternal highly active 
antiretroviral therapy (%) 
34 (50.7%) N/A 31 (67.4%) N/A 
 
0.077 
Table 1
 Haemophilus influenzae B 
Frequency (%) 
Pertussis 
Frequency (%) 
Tetanus 
Frequency (%) 
Hepatitis B 
Frequency (%) 
 Protective levels  
(>1 mg/ml) 
 Positive (“protected”) 
(>30 FDA-U/ml) 
 “Sufficient or long-
term immunity” 
(>0.1 IU/ml) 
 Positive (“protected”) 
(≥10 mIU/ml) 
 
 HIV-
exposed 
N (%) 
HIV-
unexposed  
N (%) 
Odds 
ratio 
(95% CI) 
HIV-
exposed 
N (%) 
HIV-
unexposed  
N (%) 
Odds 
ratio 
(95% CI) 
HIV-
exposed 
N (%) 
HIV-
unexposed  
N (%) 
Odds 
ratio 
(95% CI) 
HIV-
exposed 
N (%) 
HIV-
unexposed  
N (%) 
Odds 
ratio 
(95% CI) 
Week 
14 
69/101 
(68.3) 
27/58 
(46.6) 
 
1.75 
(1.17-
2.63) 
 
47/101 
(46.5) 
27/60 
(44.8) 
1.05  
(0.69-
1.58) 
 
100/100 
(100.0) 
58/58 
(100.0) 
N/A 80/80 
(100.0) 
50/51 
(98.0) 
N/A 
Week 
24 
68/94 
(72.3)) 
24/55 
(43.6) 
2.09  
(1.37-
3.17) 
 
60/85 
(70.6) 
25/53 
(47.2) 
1.80  
(1.19-
2.72) 
 
86/86 
(100.0) 
63/63 
(100.0) 
N/A 93/93 
(100.0) 
48/48 
(100.0) 
N/A 
Week 
52 
21/54 
(38.9) 
8/30 
(26.7) 
1.45  
(0.74-
2.84) 
 
31/51 
(60.4) 
18/30 
(60.0) 
1.01  
(0.56-
1.81)  
 
52/53 
(98.1) 
29/29 
(100.0) 
0.08  
(0.96-
1.02) 
 
28/28 
(100.0) 
20/20  
(100.0) 
N/A 
 
Table 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Haemophilus influenzae b Pertussis 
 Coefficient 
95% Confidence 
Interval 
p value Coefficient 
95% 
Confidence 
Interval 
p value 
BCG vaccination given 
at birth  
 -0.20 -0.45-0.04 0.102 
-0.14 -0.34—0.05 0.151 
HIV exposure    0.47 0.21-0.72 <0.001 0.16 -0.04-0.36 0.121 
Birth weight (kg) 0.18 -0.06-0.41 0.149 -0.02 -0.21-0.17 0.839 
Male sex  0.07 -0.17-0.31 0.567 0.15 0.33-1.28 0.128 
Table 3
Women screened: N=196
Excluded: N=16
Not meeting inclusion criteria: N=5
Refused to participate: N=2
Other reasons: N=9
Enrollment: N=180
(60 HIV unexposed, 120 HIV exposed)
Randomization to BCG at birth or delayed BCG at 14 weeks
Infants randomized to BCG at birth: N=90 (50%)
Total received intervention: N=106 (117.8%)
Protocol violations: 16 infants in the delayed 
intervention group additionally received BCG at
birth
Total vaccinated at birth that were 
HIV-exposed with Ab results: 57/106 (53.8%)
Infants randomized to delayed BCG: N=90 (50%)
Total received randomized intervention: 
N=74 (82.2%)
Did not receive allocated interventions: 
N=16 (17.8%)
Reasons: infants inadvertently vaccinated at 
birth by routine nursing sta! in labour ward
Total vaccinated at 14 weeks that were 
HIV-exposed with Ab results: 44/74 (59.5%) 
Week 14: Ab testing completed
HIB: N=79 (57 HEU)
Pertussis: N=78 (57 HEU)
Tetanus: N=77 (56 HEU)
HBV: N=68 (47 HEU) 
Week 24: Ab testing completed
HIB: N=69 (49 HEU)
Pertussis: N=66 (46 HEU)
Tetanus: N=66 (46 HEU)
HBV: N=69 (49 HEU)
Week 52: Ab testing completed
HIB: N=41 (31 HEU)
Pertussis: N=41 (32 HEU)
Tetanus: N=38 (31 HEU)
HBV: N=23 (15 HEU)
Week 14: Ab testing completed
HIB: N=80 (44 HEU)
Pertussis: N=81 (44 HEU)
Tetanus: N=81 (44 HEU)
HBV: N=63 (29 HEU)
Week 24: Ab testing completed
HIB: N=80 (44 HEU)
Pertussis: N=81 (39 HEU)
Tetanus: N=81 (40 HEU)
HBV: N=63 (42 HEU)
Week 52: Ab testing completed
HIB: N=43 (22 HEU)
Pertussis: N=42 (21 HEU)
Tetanus: N=44 (22 HEU)
HBV: N=25 (12 HEU)
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